Abstract
One of the major elements contributing to anemia in Chronic Kidney Disease (CKD) patients is iron deficiency. Iron supplementation in oral form is often not tolerated and ineffectively absorbed. Intravenous (IV) infusion is time consuming and is inconvenient in Peritoneal Dialysis (PD) patients self-treating at home. A new preparation of iron, ferumoxytol, is a carbohydrate-coated, paramagnetic iron oxide nanoparticle, which can be administered as a bolus intravenous injection, allowing the PD patient to more easily comply with current IV iron dosing regimens. Few studies have been done to evaluate the efficacy of ferumoxytol in PD population. We retrospectively reviewed the medical records of peritoneal dialysis patients who received at least one dose of ferumoxytol between January 2010 and August 2010 and observed that 17 patients showed an improvement in hemoglobin (Hb) to 1 gm/dl within a month of treatment along with a decrease in epoetin dosage in subsequent weeks.
Highlights
Anemia is a common finding in chronic kidney disease patients and is attributed to lack of iron deficiency along with decreased production of erythropoietin by the kidneys
We reviewed the medical records of peritoneal dialysis patients aged 18 years, who received at least one dose of ferumoxytol and analyzed the hematologic changes over a period of 4 months
Study design: A retrospective analysis was conducted on 9 males and 8 females aged 53.5 ± 16.6 years with average weight of 83.94 ± 22.8 kg peritoneal dialysis patients being treated with ferumoxytol for anemia at New Hospital Queens/Cornell University clinic between January 2010 and August 2010
Summary
Anemia is a common finding in chronic kidney disease patients and is attributed to lack of iron deficiency along with decreased production of erythropoietin by the kidneys. Referred to as reticuloendothelial blockade, it causes a functional iron deficiency in which iron is present but not usable for hemoglobin synthesis. As a result to overcome this blockade and iron deficit from erythropoiesis stimulating agents and blood loss, use of intravenous iron has been successful in treating anemia [2]. United States Food and Drug Administration on June 30, 2009 approved ferumoxytol for the treatment of iron deficiency anemia in adults with chronic kidney disease. If response in monitoring parameters is not seen (hemoglobin level, ferritin level, transferrin saturation, blood pressure) regimen can be repeated again [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
